Cepheid Plans to Buy Plastics Firm, Signs Second Agreement to Increase Adoption of TB Test | GenomeWeb

NEW YORK (GenomeWeb News) – One day after saying that its third-quarter revenues would fail to meet expectations, Cepheid said on Thursday that it is acquiring a plastics company and bringing at least some of its molding operations in-house.

Company officials also said that the firm has signed the second of three agreements aimed at increasing adoption of its Xpert MTB/RIF test in resource-poor areas of the world with multi-drug-resistant tuberculosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.